Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -665.65% is 70% above its 5-year average of -2249.54%, near the low end of its 5-year range (-71018.75%–449548.28%).
100.90% below its 12-month average of 73798.96%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 31.92%.
EBITDA MARGIN
-665.65%
EBITDA MARGIN AVG TTM
73798.96%
EBITDA MARGIN AVG 3Y
-3905.72%
EBITDA MARGIN AVG 5Y
-2249.54%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-100.90%
CURRENT VS 3Y AVG
+82.96%
CURRENT VS 5Y AVG
+70.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Vir Biotechnology, Inc.
Market Cap
$1.96B
EBITDA Margin
-665.65%
TTM Avg
73798.96%
3Y Avg
-3905.72%
5Y Avg
-2249.54%
Market Cap
$1.97B
EBITDA Margin
7.12%
TTM Avg
6.21%
3Y Avg
-1.19%
5Y Avg
-11.55%
Market Cap
$1.98B
EBITDA Margin
1.74%
TTM Avg
-0.52%
3Y Avg
3.36%
5Y Avg
2.51%
Market Cap
$1.92B
EBITDA Margin
-13.52%
TTM Avg
-19.53%
3Y Avg
-24.36%
5Y Avg
-23.78%
Market Cap
$2.02B
EBITDA Margin
40.34%
TTM Avg
23.31%
3Y Avg
-20.04%
5Y Avg
-112.62%
Market Cap
$2.02B
EBITDA Margin
-111.53%
TTM Avg
-109.12%
3Y Avg
-103.85%
5Y Avg
-277.10%
Market Cap
$1.89B
EBITDA Margin
-864.28%
TTM Avg
-1007.63%
3Y Avg
-1530.50%
5Y Avg
-1530.50%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | $1.96B | -665.65% | 73798.96% | -3905.72% | -2249.54% |
| AxoGen, Inc. (AXGN)vs › | $1.95B | 0.15% | 1.29% | -6.34% | -9.86% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 7.12% | 6.21% | -1.19% | -11.55% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | 1.74% | -0.52% | 3.36% | 2.51% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | N/A | N/A | N/A | N/A |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | -13.52% | -19.53% | -24.36% | -23.78% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 40.34% | 23.31% | -20.04% | -112.62% |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | -111.53% | -109.12% | -103.85% | -277.10% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | -864.28% | -1007.63% | -1530.50% | -1530.50% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 39.14% | 19.43% | -11.55% | -189.29% |
Gross Margin
82.9%
EBITDA Margin
-665.6%
Operating Margin
-682.7%
Net Margin
-83.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 31.92% |
| 2026-03-31 | 449548.28% |
| 2025-12-31 | -52.62% |
| 2025-09-30 | -71018.75% |
| 2025-06-30 | -9514.00% |
| 2025-03-31 | -4507.92% |
| 2024-12-31 | -923.42% |
| 2024-09-30 | -9596.97% |
| 2024-06-30 | -5020.16% |
| 2024-03-31 | -134.04% |
| 2023-12-31 | -801.44% |
| 2023-09-30 | -6902.08% |
| 2023-06-30 | -5542.22% |
| 2023-03-31 | -218.77% |
| 2022-12-31 | -300.65% |
| 2022-09-30 | 52.50% |
| 2022-06-30 | 550.41% |
| 2022-03-31 | 82.39% |
| 2021-12-31 | 70.54% |
| 2021-09-30 | -50.09% |
| 2021-06-30 | 35.33% |
| 2021-03-31 | -25988.60% |
| 2020-12-31 | -35569.77% |
| 2020-09-30 | -45843.09% |
| 2020-06-30 | -41.78% |
| 2020-03-31 | -1240.12% |
| 2019-12-31 | -6417.86% |
| 2019-09-30 | -19608.44% |
| 2019-06-30 | -40274.42% |
| 2019-03-31 | -175047.06% |
| 2018-12-31 | -431633.33% |
| 2018-09-30 | -29477.19% |
| 2018-06-30 | -1178.96% |
| 2018-03-31 | -1178.96% |
